157
Views
8
CrossRef citations to date
0
Altmetric
Drug Evaluation

Epoprostenol in pulmonary arterial hypertension

, MD & , MD PhD
Pages 83-90 | Published online: 15 Dec 2008
 

Abstract

Background: Pulmonary arterial hypertension (PAH) is a devastating disease leading to right heart failure and death in a relatively young patient population. In recent years novel PAH specific therapies have become available. Objective: To determine the place of epoprostenol in current PAH treatment strategies. Methods: An extensive Medline search was performed to evaluate the use of epoprostenol in PAH. Data from both human and animal studies were reviewed. Results/conclusion: Epoprostenol is an effective and potent treatment in pulmonary arterial hypertension and has greatly improved survival, exercise capacity, PAH symptoms, pulmonary haemodynamics and disease progression. A main disadvantage is that it can only be delivered through a continuous intravenous pump infusion.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 727.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.